Q-omics provides the consensus-scored STK32C profile across patient tissues and cancer cell-line models. STK32C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STK32C is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, STK32C protein abundance shows 22,109 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where STK32C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK32C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK32C survival associations across molecular data types. STK32C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK32C RNA expression–survival associations across cancer types. High STK32C expression shows unfavorable associations in KIRC, UCEC, LIHC, ACC and LAML, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STK32C RNA expression.
This table summarizes STK32C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for STK32C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK32C shows lower tumor expression in KICH and higher tumor expression in BLCA, COAD, HNSC, STAD and LIHC. The BLCA box plot shows higher STK32C RNA expression in tumor versus normal tissue (log2 FC = +1.135, t-test p < 0.001).
This table shows molecular features associated with STK32C in patient tissues and cancer cell lines. In patient samples, STK32C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STK32C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and PANCREAS.
